ÂÜÀòÂÒÂ×

Luiz Belardinelli is the current Chief Medical Officer at InCarda Therapeutics. Luiz has also previously worked as the Vice President of Technical Operations at Forsight Vision5 and as the Vice President of Product Development at S.E.A. Medical Systems, Inc.

Belardinelli has extensive experience in product development and improving manufacturing lines. At Forsight Vision5, they were responsible for re-organizing the staff and improving manufacturing line reliability and throughput. Luiz also led and reviewed technical progress against goals, established processes and practices to meet medical device and drug product regulatory/quality expectations, instituted program management practices, manufactured and randomized supplies for two multiple arm masked trials and created product development plans, timeliness and budgets for two Phase II programs / and Phase III / scale-up / commercialization. Allergan acquired VISION-5 for $95M up-front plus milestone payments.

At S.E.A. Medical Systems, Inc., Belardinelli revamped product development plans and timelines for S.E.A.'s lead products, improved the operation of the engineering organization, established Product Development and Risk Management processes, improved scientific data sharing and communication and led S.E.A.'s technology structured troubleshooting effort.

Belardinelli's experience in product development and manufacturing makes him an asset to any company. Their work history shows a commitment to improving efficiency and productivity in any organization they are a part of.

They are on a team with Natalia Dickinson - VP, Quality Assurance, Carlos Schuler - Chief Operation & Technology Officer & Co-Founder, and Phil Kletnieks - Senior Director, Analytical Chemistry. Luiz Belardinelli reports to Grace E. Colón, President & CEO. and Christopher Dufton - SVP, Clinical Development reports to Luiz Belardinelli.